SAFETY AND TOLERABILITY OF ONCE-DAILY ORAL KALLIKREIN INHIBITOR BCX7353 IN PHASE 3 APEX-2 HAE STUDY

被引：3
|
作者：
Riedl, M.
Lumry, W.
Banerji, A.
Aygoren-Pursun, E.
Bernstein, J.
Maurer, M.
Cicardi, M.
Christiansen, S.
Zuraw, B.
Dobo, S.
Cornpropst, M.
Iocca, H.
Nagy, E.
Murray, S.
Collis, P.
Sheridan, W.
Johnston, D.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2019年 / 123卷 / 05期
关键词：
D O I：
10.1016/j.anai.2019.08.258
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P154
引用
收藏
页码：S28 / S29
页数：3
相关论文
共 50 条
  • [1] ORAL PROPHYLAXIS WITH BCX7353 REDUCES HAE ATTACK RATES AND IS WELL-TOLERATED: APEX-2 STUDY RESULTS
    Zuraw, B.
    Lumry, W.
    Banerji, A.
    Aygoren-Pursun, E.
    Bernstein, J.
    Johnston, D.
    Christiansen, S.
    Riedl, M.
    Cicardi, M.
    Maurer, M.
    Cornpropst, M.
    Dobo, S.
    Iocca, H.
    Nagy, E.
    Murray, S.
    Collis, P.
    Sheridan, W.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S27 - S27
  • [2] Preclinical Characterization of BCX7353, an Oral Plasma Kallikrein Inhibitor, for the Treatment of Hereditary Angioedema (HAE)
    Chen, Xilin
    Kotian, Pravin
    Wilson, Ramanda
    Parker, Cynthia D.
    Babu, Y. S.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (02) : AB230 - AB230
  • [3] BCX7353, a once-daily oral kallikrein inhibitor, is effective and safe in the prophylaxis of acute attacks in patients with hereditary angioedema: Attack-level analysis of the APeX-1 study
    Aygoeren, E.
    Bygum, A.
    Steiner, U.
    Magerl, M.
    Panovska, Grivcheva, V
    Farkas, H.
    Huissoon, A.
    Graff, J.
    Lleonart, R.
    Rae, W.
    Aberer, W.
    Longhurst, H.
    Smith, W.
    Zanichelli, A.
    Cancian, M.
    Guilarte, M.
    Triggiani, M.
    Gompels, M.
    Fang, L.
    Cornpropst, M.
    Clemons, D.
    Collis, P.
    Dobo, S.
    Sheridan, W. P.
    Maurer, M.
    Cicardi, M.
    [J]. ALLERGY, 2017, 72 : 584 - 585
  • [4] Long-term safety and tolerability of Berotralstat (BCX7353) for Hereditary Angioedema (HAE) prophylaxis: APeX-S study results
    Farkas, H.
    Wu, A. Y.
    Kiani, S.
    Reshef, A.
    Stobiecki, M.
    Kinaciyan, T.
    Maurer, M.
    Aygoren-Pursun, E.
    Dix, D.
    Dobo, S.
    Iocca, H.
    Murray, S.
    Sheridan, W. P.
    Peter, J.
    [J]. ALLERGY, 2020, 75 : 58 - 59
  • [5] Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study
    Aygoren-Pursun, E.
    Johnston, D.
    Banerji, A.
    Bernstein, J. A.
    Yang, W. H.
    Fritz, S.
    Zuraw, B.
    Mcneil, D.
    Cornpropst, M.
    Murray, S.
    Nagy, E.
    Collis, P.
    Craig, T.
    [J]. ALLERGY, 2020, 75 : 457 - 458
  • [6] Relative Reductions in Attack Rate With Prophylactic Berotralstat (BCX7353) in Subjects with Hereditary Angioedema (HAE): Responder Analysis from the APeX-2 Study
    Lumry, William
    Maurer, Marcus
    Zuraw, Bruce
    Banerji, Aleena
    Riedl, Marc
    Johnston, Douglas
    Aygoren-Pursun, Emel
    Jacobs, Joshua
    Gower, Richard
    Wedner, H. James
    Sitz, Karl
    Magerl, Markus
    Cornpropst, Melanie
    Elder, Jennifer
    Iocca, Heather
    Nagy, Eniko
    Murray, Sharon
    Collis, Philip
    Sheridan, William
    Christiansen, Sandra
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB105 - AB105
  • [7] Oral Prophylaxis with Berotralstat (BCX7353) Reduces Use of Standard of Care (SOC) On-demand Medication in Patients with Hereditary Angioedema (HAE): APeX-2 Study Results
    Bernstein, Jonathan
    Zuraw, Bruce
    Aygoren-Pursun, Emel
    Li, Huamin
    Busse, Paula
    Johnston, Douglas
    Maurer, Marcus
    Lumry, William
    Riedl, Marc
    Jacobs, Joshua
    Sitz, Karl
    Gagnon, Remi
    Clemons, Desiree
    Dobo, Sylvia
    Nagy, Eniko
    Murray, Sharon
    Collis, Philip
    Sheridan, William
    Banerji, Aleena
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB106 - AB106
  • [8] Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)
    Wedner, H. James
    Aygoeren-Puersuen, Emel
    Bernstein, Jonathan
    Craig, Timothy
    Gower, Richard
    Jacobs, Joshua S.
    Johnston, Douglas T.
    Lumry, William R.
    Zuraw, Bruce L.
    Best, Jessica M.
    Iocca, Heather A.
    Murray, Sharon C.
    Desai, Bhavisha
    Nagy, Eniko
    Sheridan, William P.
    Kiani-Alikhan, Sorena
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (06): : 2305 - +
  • [9] Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE)
    Kotian, Pravin L.
    Wu, Minwan
    Vadlakonda, Satish
    Chintareddy, Venkat
    Lu, Pengcheng
    Juarez, Luis
    Kellogg-Yelder, Debra
    Chen, Xilin
    Muppa, Saritha
    Chambers-Wilson, Ramanda
    Parker, Cynthia Davis
    Williams, Jason
    Polach, Kevin J.
    Zhang, Weihe
    Raman, Krishnan
    Babu, Yarlagadda S.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (17) : 12453 - 12468
  • [10] Long-term safety and effectiveness of berotralstat (BCX7353) for the prophylaxis of hereditary angioedema (HAE) attacks: Results from the APeX-S study
    Kiani, Sorena
    Wu, Adrian
    Peter, Jonathan
    Reshef, Avner
    Maurer, Marcus
    Stobiecki, Marcin
    Kinaciyan, Tamar
    Aygoeren-Puersuen, Emel
    Best, Jessica
    Cornpropst, Melanie
    Sheridan, William P.
    Farkas, Henriette
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (01): : 172 - 173
12345